Kwok Ryan M, Tran Tram T
Division of Gastroenterology/Hepatology, Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD, 20889, USA.
Cedars-Sinai Medical Center Liver Transplantation, 8700 Beverly Blvd., Los Angeles, CA, 90048, USA.
Curr Treat Options Gastroenterol. 2017 Jun;15(2):305-315. doi: 10.1007/s11938-017-0134-2.
Chronic hepatitis C (HCV) is a hepatotropic virus which, when untreated, can lead to progressive inflammation and fibrosis resulting in cirrhosis, hepatocellular carcinoma (HCC), and decompensations related to end-stage liver disease. The relatively recent introduction of all oral, interferon-free, direct-acting antiviral medications against HCV has transformed the management of these patients. Previous treatment regimens were prolonged, poorly tolerated, and frequently did not result in cure. Current therapies achieve sustained viral response (SVR) in the vast majority of patients including those with decompensated liver disease; a previously challenging population to treat. These successes will result in significant numbers of cirrhotic patients requiring management after SVR. Although many complications of cirrhosis are improved in this setting, regular follow-up of HCC, esophageal varices, and other sequelae of cirrhosis will be necessary. This chapter will review the management of cirrhosis in HCV patients achieving cure.
慢性丙型肝炎(HCV)是一种嗜肝病毒,若不进行治疗,可导致进行性炎症和纤维化,进而引发肝硬化、肝细胞癌(HCC)以及与终末期肝病相关的失代偿。相对近期出现的全口服、无干扰素、直接作用的抗HCV抗病毒药物彻底改变了这些患者的治疗方式。以前的治疗方案疗程长、耐受性差,且常常无法实现治愈。目前的疗法在绝大多数患者中都能实现持续病毒学应答(SVR),包括那些患有失代偿性肝病的患者;这是以前治疗颇具挑战性的一类人群。这些成功将导致大量肝硬化患者在实现SVR后仍需要管理。尽管在这种情况下肝硬化的许多并发症有所改善,但仍有必要对HCC、食管静脉曲张和肝硬化的其他后遗症进行定期随访。本章将综述治愈HCV的患者中肝硬化的管理。